Development code · Small Molecule
AQW-051
AQW-051 is a development code for VQW-765, developed by Vanda Pharmaceuticals Inc..
- Status
- Phase 3 for Social anxiety disorder
- Mechanism
- alpha7 nAChR Partial agonist
- Developer
- Vanda Pharmaceuticals Inc.
Programs
- VQW-765 for Social anxiety disorderPhase 3Recruiting
Also known as
- VQW-765
- AQW051
- (3R)-3-{[6-(4-methylphenyl)pyridin-3-yl]oxy}-1-azabicyclo[2.2.2]octane
- 669770-29-0